Author

Dominique Boudreau

Institution: Hôpital du Saint-Sacrement

Observed institution: Hôpital du Saint-Sacrement

ORCID: 0009-0004-7422-6659

Observed ORCID: 0009-0004-7422-6659

OpenAlex ID: A5133831847

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

2025 · Tess Aalto, Maria Abacan, et al. · Cancer Cell · 9

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial

2026 · Sibylle Loibl, Gong Tang, et al. · Nature Medicine · 3

Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab

2026 · Marija Balic, Gong Tang, et al. · JCO Precision Oncology

Abstract CT013: Whole-exome sequencing tumor-informed circulating tumor DNA detection after completion of neoadjuvant treatment predicts non-pCR and distant recurrence in patients with early triple-negative breast cancer (TNBC) — Results from a sub-study of the NSABP B-59/GBG-96-GeparDouze Trial

2026 · Marija Balic, Gong Tang, et al. · Cancer Research

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2− and Triple-Negative Breast Cancer in Canada: The HER2− TRENDS Study

2026 · Karen Gambaro, Kahina Rachedi, et al. · Advances in Therapy

Works count: 5

Citation count: 12

H-index: 2

I10-index: